Mitochondrial DNA haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients.
OBJECTIVE
Tacrolimus (Tac) is an immunosuppressive drug widely used to avoid organ rejection. New-onset diabetes after transplantation (NODAT) is a major complication among transplanted patients who receive Tac. The increased risk for NODAT could be partly mediated by the effect of Tac on mitochondria from pancreatic beta-cells. Common and rare mitochondrial DNA variants have been linked to the risk of diabetes. Our aim was to determine whether mtDNA polymorphisms/haplogroups were associated with NODAT in Tac-treated kidney transplanted.


METHODS
Seven polymorphisms that define the common European haplogroups were determined in 115 NODAT and 197 no-NODAT patients.


RESULTS
Haplogroup H was significantly more frequent in the NODAT group (50% vs. 35%; p=0.01, OR=1.82). There was no difference between patients without and with (n=106) D2M prior to the transplant.


CONCLUSIONS
Mitochondrial haplogroup H was associated with the risk for NODAT among Tac-treated transplanted patients. The reported differences between the mtDNA variants could explain the increased NODAT-risk among H-patients.
Genética Molecular, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Beatriz
B
Tavira
Genética Molecular, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Juan
J
Gómez
Nefrología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Carmen
C
Díaz-Corte
Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Centro de Investigaciones Biomédicas En Red de Enfermedades Raras (CIBERER), Universidad de Zaragoza, Zaragoza, Spain.
Laura
L
Llobet
Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Centro de Investigaciones Biomédicas En Red de Enfermedades Raras (CIBERER), Universidad de Zaragoza, Zaragoza, Spain.
Eduardo
E
Ruiz-Pesini
Nefrología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; Fundación Renal I. Alvarez de Toledo, Madrid, Spain.
Francisco
F
Ortega
Genética Molecular, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; Fundación Renal I. Alvarez de Toledo, Madrid, Spain; Universidad de Oviedo, Oviedo, Spain. Electronic address: eliecer.coto@sespa.princast.es.
Eliecer
E
Coto
D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D004272:DNA, Mitochondrial / Q000235:genetics*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use
D004272:DNA, Mitochondrial; D007166:Immunosuppressive Agents; D016559:Tacrolimus
Haplogroups; Mitochondria; Post-transplant diabetes; Tacrolimus